Piramal Phytocare Share Price Breached Upper Circuit Piramal Phytocare share price surged up by a massive 19.99 per cent in the Monday’s trading session to breach the upper circuit. Today’s High lights Spurt in Volume by more than 6.92 times Breached Upper Circuit Rs. 100.10 The Fundamentals at a Glance Exchange Symbol Sector Current Price * (Rs.) Face Value (Rs.) 52 Week High (Rs.) 52 Week Low (Rs.) Life Time high (Rs.) Life Time low (Rs.) Average Daily Movement [ADM] Average Volume [20 days] 1 Month Return (%) Consolidated FY 15-16 PE Ratio Consolidated Trailing PE Ratio Standalone FY 15-16 PE Ratio Standalone Trailing PE Ratio Book Value Market Cap % of Promoter holding pledged
PIRPHYTO (NSE) PHARMA 99.65 10 140.60 (28-Dec-15) 47.10 (29-Feb-16) 519.00 (29-May-08) 3.10 (23-Dec-11) 6.28 33460 -20.6 0 0 0 0 1.92 215.60 (Cr) 0
Piramal Phytocare as a top 500 stock Piramal Phytocare is one of the top 500 Shares identified by Dynamic research team at the end of every quarter out of 1700 plus Shares on the National Stock Exchange. Piramal Phytocare has strong fundamentals. Strong Fundamentals mean Piramal Phytocare has not made any losses in last 2 quarters, debt equity is less than 2 (not applicable for NBFC and banks) and pledge is less than 25 per cent. These top 500 Shares are safe for investment. Dynamic levels research experts provide Piramal Phytocare share price target along with share market tips for the stock with the help of our unique research tools (the ladder). These tips are updated every day, please check this page daily for new tips (visit Piramal Phytocare share price target). Sometimes the entry rate may be very far from the previous day close. The investors need to be patient, as entry at these levels will have a strong probability to give better results. The Important Levels Piramal Phytocare broke the closest resistance levels by rising massively today. Get the most important support and resistance levels of the share at Piramal Phytocare share price forecast. About Piramal Phytocare The Piramal Group is a diversified conglomerate with operations spread in more than 30 countries and with brand-presence across 100 markets around the world. Since the late 1980s, the Piramal Group has evolved from a textile-centric business to a diversified pharmaceutical-based global organization. The Piramal Group operates across sectors like healthcare, life sciences, drug discovery, healthcare information management, financial services, specialty glass packaging and real estate. As a Group the company consistently identified opportunities ahead of the curve, even when market situations suggest the opposite. The company invested in the domestic formulations business when others were focused on growing international generics. This persistence paid off when a deal with Abbott in 2010 valued our business at USD 3.72 billion, an unprecedented 9x sales and 30x EBITDA.
Disclaimer The investment advice or guidance provided by way of recommendations, reports or other ways are solely the personal views of the research team. Users are advised to use the data for the purpose of information and rely on their own judgment while making investment decision. Dynamic Equities Pvt. Ltd - SEBI Investment Advisory Reg. No.: INA300002022
Disclosure Dynamic Equities Pvt. Ltd. is a member of NSE, BSE, MCX SX and a DP with NSDL & CDSL. It is also engaged in Investment Advisory Services and Portfolio Management Services. Dynamic Commodities Pvt. Ltd., associate company, is a member of MCX & NCDEX. We declare that our activities were neither suspended nor we have defaulted with any stock exchange authority with whom we are registered. SEBI, Exchanges and Depositories have conducted the routine inspection and based on their observations have issued advise letters or levied minor penalty on for certain operational deviations. Answers to the Best of our knowledge and belief of Dynamic/ its Associates/ Research Analyst: DYNAMIC/its Associates/ Research Analyst/ his Relative: Do not have any financial interest / any actual/beneficial ownership in the subject company. Do not have any other material conflict of interest at the time of publication of the research report Have not received any compensation from the subject company in the past twelve months Have not managed or co-managed public offering of securities for the subject company. Have not received any compensation for brokerage services or any products / services or any compensation or other benefits from the subject company, nor engaged in market making activity for the subject company Have not served as an officer, director or employee of the subject company
Article Written by Nabarupa Kanjilal